Ozempic Lawsuit

The Ozempic Lawsuit has become an important legal issue as patients raise claims involving serious gastrointestinal injuries and, in separate litigation, vision loss. Ozempic is a prescription medicine containing semaglutide that doctors use to help adults with type 2 diabetes manage blood sugar.

The legal cases do not mean that every person who uses Ozempic will suffer a serious injury. Instead, plaintiffs claim that certain GLP-1 medicines caused specific medical problems and that manufacturers did not provide adequate warnings about some alleged risks.

As of 2026, major federal litigation involving GLP-1 drugs remains active. Gastrointestinal injury cases are being coordinated in MDL 3094, while claims involving non-arteritic anterior ischemic optic neuropathy, commonly called NAION, are being handled separately in MDL 3163.

Ozempic Lawsuit 2026: Latest Updates

Ozempic litigation continues to develop in 2026. Federal courts are coordinating cases involving patients who allege injuries after taking Ozempic and other GLP-1 receptor agonist medicines.

The gastrointestinal cases are part of MDL 3094 in the U.S. District Court for the Eastern District of Pennsylvania. The court states that these cases involve similar questions about GLP-1 medicines and alleged gastrointestinal injuries.

The drugs involved in the GI litigation include Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro. The allegations include questions about gastroparesis and other gastrointestinal injuries and whether manufacturers adequately warned patients and prescribing doctors.

Novo Nordisk and Eli Lilly deny the allegations made against them. This distinction is important because allegations in a lawsuit are not the same as proven facts or court findings.

A second federal MDL focuses on NAION, a condition that can cause sudden vision loss. MDL 3163 is also pending in the Eastern District of Pennsylvania and includes claims involving several GLP-1 drugs.

What Is the Ozempic Lawsuit?

The term “Ozempic lawsuit” generally refers to product liability cases filed by people who claim they suffered serious injuries after using Ozempic.

Ozempic contains semaglutide and belongs to a group of medicines known as GLP-1 receptor agonists. These medicines affect blood sugar, appetite, and digestion.

Plaintiffs generally argue that they used a GLP-1 medicine as prescribed and later developed an injury that they believe the medicine caused or contributed to.

Many cases also involve failure-to-warn allegations. Plaintiffs may argue that a manufacturer knew or should have known about a risk but did not adequately communicate it to patients or health professionals.

Manufacturers can dispute these claims. They may challenge whether the drug caused a particular injury, whether warnings were adequate, or whether other health factors explain the patient’s condition.

A lawsuit therefore does not automatically prove that Ozempic caused an injury. Each claim depends on medical evidence, legal arguments, applicable law, and the facts of the individual case.

Why Are People Filing Ozempic Lawsuits?

People have filed lawsuits after reporting serious health problems that they believe developed because of GLP-1 medication use.

The federal GI litigation specifically addresses allegations involving gastroparesis and other gastrointestinal injuries. Court documents show that plaintiffs have identified several types of claimed injuries.

Some patients say their symptoms required hospital treatment, diagnostic testing, medication, dietary changes, or other medical care.

Others claim that their medical problems caused financial losses or had a major effect on their daily activities.

Failure to Warn Claims

Failure to warn is a central issue in many pharmaceutical product liability lawsuits.

A plaintiff may argue that a drug manufacturer did not provide a sufficient warning about a serious risk associated with its product.

The federal court describes common factual questions in MDL 3094 as including whether manufacturers knew or should have known that GLP-1 drugs could cause alleged gastrointestinal injuries and whether warnings were adequate.

However, manufacturers deny the allegations. Courts must evaluate the evidence and applicable law before determining whether any defendant is legally responsible.

Claims Against Ozempic Manufacturer Novo Nordisk

Novo Nordisk manufactures Ozempic. Some lawsuits involving the drug name Novo Nordisk entities as defendants.

Plaintiffs may raise claims involving alleged failure to warn, design issues, warranties, or other product liability theories depending on the case and state law.

Novo Nordisk disputes allegations made in the litigation. Readers should therefore avoid treating claims made in complaints as established medical or legal facts.

What Plaintiffs Allege

Plaintiffs generally allege that GLP-1 medicines caused or contributed to serious injuries and that warnings about certain risks were inadequate.

The GI MDL court has stated that the consolidated cases share factual questions concerning alleged gastrointestinal injuries and representations about product safety.

The newer NAION litigation includes allegations involving vision injuries. Court records describe claims involving failure to warn, design defect, and breach of warranties.

Ozempic Lawsuit and Serious Side Effects

Not every known side effect of a medicine creates grounds for a lawsuit.

Product liability cases generally focus on alleged injuries that plaintiffs claim resulted from a product and on whether a manufacturer had a legal duty that it failed to meet.

Court documents from MDL 3094 identify a range of claimed injuries, including gastroparesis, ileus, intestinal obstruction, ischemic bowel or colitis, gallbladder injury, pancreatitis, aspiration, micronutrient deficiency, and other conditions.

These are allegations within litigation. Inclusion on a court claim form does not itself establish that a GLP-1 medicine caused each condition.

Gastroparesis or Stomach Paralysis

Gastroparesis is a condition in which the stomach empties food more slowly than normal even though there is no mechanical blockage causing the delay.

Symptoms can include nausea, vomiting, feeling full quickly, abdominal discomfort, and difficulty eating normal meals.

Gastroparesis has become one of the major injuries discussed in GLP-1 litigation.

The federal court specifically identifies gastroparesis as one of the gastrointestinal injuries at issue in MDL 3094.

Intestinal and Bowel Obstruction

An intestinal obstruction occurs when food, liquid, gas, or digestive material cannot move normally through the intestines.

Depending on the cause and severity, a blockage can become a medical emergency and may require hospital care.

Intestinal obstruction is among the claimed injuries listed in court documents used in the federal GLP-1 litigation.

Ileus and Digestive Problems

Ileus involves reduced or absent movement of material through the intestines without a physical blockage being the main cause.

Symptoms may include abdominal swelling, pain, nausea, vomiting, constipation, or difficulty passing gas.

Ileus is also specifically listed among the injuries plaintiffs may identify in the GI MDL.

Severe Vomiting and Stomach Problems

Nausea and vomiting are among the digestive symptoms discussed in GLP-1 litigation.

Severe or persistent vomiting can become more serious when it contributes to dehydration, nutritional problems, or a need for medical treatment.

Earlier plaintiff fact sheets in MDL 3094 included nausea, vomiting, constipation, abdominal pain, diarrhea, dehydration, and malnutrition among claimed injuries or symptoms.

Also Read: pima county sheriff lawsuit

Vision Loss and NAION

Vision-loss allegations now form a separate major part of GLP-1 litigation.

NAION stands for non-arteritic anterior ischemic optic neuropathy. It involves damage to the optic nerve associated with reduced blood flow and can cause sudden vision loss.

The federal Judicial Panel created MDL 3163 for GLP-1 product liability actions involving allegations of NAION.

That litigation is separate from MDL 3094, which primarily addresses gastrointestinal injuries.

Ozempic Gastroparesis Lawsuit

Gastroparesis claims have received significant attention because delayed stomach emptying relates directly to how GLP-1 drugs affect digestion.

Plaintiffs may claim that their symptoms became severe or continued after using a GLP-1 medicine.

A diagnosis alone does not prove that Ozempic caused a person’s gastroparesis. Lawyers and medical experts may examine medication history, medical records, other medical conditions, timing, and alternative causes.

How Ozempic May Affect Stomach Emptying

GLP-1 medicines can affect the digestive process, including the rate at which the stomach empties.

That effect is one reason digestive symptoms have become important in litigation.

The legal question is more complex than simply showing that a medicine affects digestion. Plaintiffs generally must establish a legally sufficient connection between the product and the injury they claim.

Symptoms Reported in Gastroparesis Claims

A person with gastroparesis may experience nausea, vomiting, abdominal pain, bloating, early fullness, or difficulty eating.

Symptoms vary greatly from one person to another.

Someone experiencing severe or persistent digestive symptoms should seek medical advice rather than relying on lawsuit information to diagnose a medical condition.

Evidence Used in Gastroparesis Lawsuits

Medical documentation can play an important role in a gastroparesis claim.

Relevant evidence may include prescription history, physician notes, diagnostic testing, emergency room records, hospital records, and information showing when symptoms started.

Records showing other health conditions can also matter because defendants may argue that another condition caused or contributed to the patient’s symptoms.

Ozempic Vision Loss Lawsuit

Vision-loss claims have developed into a distinct area of GLP-1 product liability litigation.

In late 2025, federal cases alleging NAION were centralized into MDL 3163. During 2026, the court has continued issuing case-management and discovery orders.

The MDL includes claims involving drugs sold under several brand names, including Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro, and Zepbound.

What Is NAION?

NAION is a serious eye condition affecting the optic nerve.

The optic nerve carries visual information from the eye to the brain. Damage to this nerve can cause partial or significant loss of vision.

A person who experiences sudden vision changes should seek urgent medical attention. Legal information should never replace evaluation by an eye specialist or other qualified health professional.

Ozempic and Blindness Claims

Some plaintiffs allege that GLP-1 drugs caused or contributed to NAION and resulting vision loss.

These claims are now being coordinated so courts can manage common questions more efficiently.

The defendants can contest causation and other elements of the claims. The creation of an MDL does not mean a court has ruled that Ozempic causes NAION.

Current Status of NAION Lawsuits

MDL 3163 remains active in 2026.

Court orders show that the litigation has moved through organizational steps involving leadership counsel, evidence preservation, electronic information, discovery, and other pretrial matters.

A July 2, 2026 order addressed early discovery and motions concerning issues shared across cases, showing that the litigation remains in an active pretrial phase.

Latest Ozempic Lawsuit Updates

The most important development for readers is that there are now two major federal GLP-1 MDLs addressing different categories of alleged injuries.

MDL 3094 focuses on gastrointestinal injuries, while MDL 3163 focuses on NAION.

Both proceedings are pending before Judge Karen Spencer Marston in the Eastern District of Pennsylvania.

Current Number of Ozempic and GLP-1 Lawsuits

The number of cases in an MDL can change frequently as new actions enter or leave the proceeding.

The Judicial Panel on Multidistrict Litigation publishes updated pending MDL reports. Its latest available report is dated August 3, 2026.

Readers should be careful with websites that quote a case count without giving a date. A number that was correct several months ago may no longer describe the current docket.

It is also important to distinguish Ozempic-only cases from the total number of GLP-1 cases because the federal proceedings involve multiple medicines.

Ozempic MDL 3094 Update

MDL 3094 was created to coordinate federal GLP-1 product liability cases involving alleged gastrointestinal injuries.

The MDL continues to move through pretrial proceedings in 2026.

Court records list orders dealing with plaintiff fact sheets, streamlined docket procedures, short-form complaints, discovery, depositions, electronic information, and scheduling.

The court also schedules monthly status conferences as the litigation progresses.

GLP-1 Vision Loss MDL 3163 Update

MDL 3163 is newer than the gastrointestinal proceeding.

It addresses cases in which plaintiffs allege that GLP-1 medicines caused NAION.

The court issued multiple management orders during 2026, including orders concerning plaintiff leadership, Science Day, evidence preservation, electronic information, and early discovery.

Recent Court Developments

One important feature of large pharmaceutical litigation is that courts often address broad legal or scientific questions before individual cases reach trial.

These issues can influence many cases at once.

In the GI proceeding, the court has developed procedures for fact sheets and short-form complaints while managing common issues across the litigation.

In the NAION proceeding, a July 2026 order addressed early discovery on cross-cutting issues.

What Happens Next in the Litigation?

Large MDLs generally move through several stages.

The parties exchange documents and evidence, courts decide important legal questions, experts may analyze scientific issues, and representative cases may eventually receive focused attention for trial preparation.

The exact path can change as judges issue new orders.

For that reason, predictions about an exact Ozempic settlement or trial date should be treated cautiously unless they come from an actual court order.

Is the Ozempic Lawsuit a Class Action?

The federal personal injury litigation should not simply be described as one class action.

Many Ozempic and other GLP-1 personal injury cases have instead been coordinated through multidistrict litigation.

This distinction matters because MDLs and class actions work differently.

Ozempic Lawsuit vs. Class Action

In a class action, one or more representatives pursue claims for a larger group whose members share qualifying characteristics.

In an MDL, individual lawsuits generally remain separate cases even though the court coordinates common pretrial issues.

This allows courts to handle shared discovery and legal questions more efficiently.

What Is Multidistrict Litigation?

Multidistrict litigation brings federal civil cases involving common factual questions before one district court for coordinated or consolidated pretrial proceedings.

Federal law allows these transfers when centralization improves convenience and promotes efficient handling of the cases.

It does not automatically combine every plaintiff into one single lawsuit.

Why Ozempic Cases Are Consolidated

Many GLP-1 cases raise similar questions about the drugs, warnings, alleged risks, scientific evidence, and manufacturer conduct.

Handling those common issues in one court can reduce repeated discovery and inconsistent pretrial decisions.

MDL 3094 centralizes GI injury cases, while MDL 3163 separately centralizes NAION cases.

Who Qualifies for an Ozempic Lawsuit?

There is no single universal checklist that guarantees someone qualifies for an Ozempic lawsuit.

Eligibility depends on the facts of the case, the injury, drug use, medical history, filing deadline, and applicable state law.

A lawyer reviewing a case may look for evidence connecting the patient’s use of Ozempic with a medically documented injury.

Basic Eligibility Requirements

Potential claims generally require more than simply having taken Ozempic.

A claimant may need proof that they used the medicine, suffered a legally recognized injury, and have evidence supporting a connection between the medicine and that injury.

The person must also bring the claim within the applicable legal deadline.

Medical Conditions That May Qualify

The injuries being litigated are broader than gastroparesis alone.

Current GI MDL documents identify claimed injuries such as gastroparesis, ileus, intestinal obstruction, ischemic bowel or ischemic colitis, necrotizing pancreatitis, gallbladder injury, micronutrient deficiency, aspiration, and others.

NAION claims are being handled in the separate vision-loss MDL.

Whether any particular diagnosis supports a viable lawsuit requires an individual legal and medical review.

Medical Records and Evidence You May Need

Useful records may include proof of an Ozempic prescription, pharmacy records, medical notes, hospital records, diagnostic tests, and treatment history.

A timeline can also be useful.

It may show when a patient started Ozempic, how long they used it, when symptoms began, when they stopped treatment, and when doctors diagnosed the condition.

Who May Not Qualify?

Taking Ozempic without experiencing an injury generally does not create the same type of personal injury claim being pursued in these MDLs.

A case may also face difficulties when there is no medical documentation, the injury has a strong unrelated cause, or the filing deadline has expired.

Only a qualified attorney can assess eligibility under the law that applies to an individual case.

How to File an Ozempic Lawsuit

Filing a pharmaceutical lawsuit involves more than completing a simple online form.

A potential claimant normally needs to establish medication use, injury, medical treatment, timing, and other facts.

Legal requirements can differ by state and by the type of claim.

Gather Your Medical Records

Medical records are among the most important documents in a drug injury case.

They may show diagnoses, symptoms, treatment, hospitalization, testing, surgery, and the patient’s health before and after taking the medication.

Complete records can also help identify other possible causes of the injury.

Document Your Ozempic Use

Patients should keep legitimate records showing when they received and used the medicine.

Prescription records, pharmacy history, medical charts, insurance records, and prescribing physician records may provide useful evidence.

Patients should not alter or create records. Authentic documentation is important in any legal proceeding.

Review Your Injuries and Diagnosis

A clear diagnosis can be important when evaluating a potential claim.

Symptoms alone may not always establish the underlying medical condition.

Medical professionals can determine whether diagnostic tests or specialist evaluations are needed.

Understand the Filing Deadline

Every lawsuit is subject to time limits.

These limits are often called statutes of limitations, and they can vary significantly depending on the state and circumstances.

Waiting too long can potentially prevent a person from pursuing a claim.

Speak With a Qualified Attorney

Product liability law can be complex, especially when an MDL involves thousands of records, scientific questions, and different state laws.

A qualified lawyer can review the person’s medical history, medication use, diagnosis, deadlines, and potential legal options.

People should verify a lawyer’s credentials and understand any fee agreement before hiring legal counsel.

Ozempic Lawsuit Settlement and Compensation

Settlement is one of the most searched topics connected with Ozempic litigation.

However, readers should separate confirmed settlement information from online estimates.

An advertisement or article that predicts a particular payout does not establish what an actual claimant will receive.

Has There Been an Ozempic Settlement?

The major federal Ozempic and GLP-1 personal injury proceedings remain active.

The court records discussed here show continuing pretrial management rather than a completed global resolution of the litigation.

Therefore, hypothetical settlement values should not be presented as confirmed payouts.

Future developments could change the status of the litigation.

Potential Ozempic Lawsuit Settlement Amounts

No one can reliably determine a universal settlement amount before actual settlements, verdicts, or compensation programs establish meaningful benchmarks.

Online estimates can vary widely because they are usually based on assumptions rather than guaranteed results.

Any eventual value could depend heavily on the severity and permanence of the injury.

What Factors Could Affect Compensation?

Potential case value may depend on medical expenses, injury severity, length of treatment, lost income, permanent impairment, and other damages allowed under applicable law.

Causation is also critical.

A strong medical record does not automatically prove legal responsibility, but missing or inconsistent records can make a claim more difficult to establish.

Types of Damages Plaintiffs May Seek

Depending on applicable law, plaintiffs may seek compensation for certain medical costs, lost wages, future financial losses, pain and suffering, or other legally recognized damages.

The available damages differ from case to case.

Some states also place limits or special rules on particular categories of damages.

How Much Could an Ozempic Lawsuit Be Worth?

There is no fixed value for an Ozempic lawsuit.

Two patients who used the same medicine may have very different injuries, medical histories, expenses, and long-term outcomes.

Case value also depends on whether the claimant can establish the legal elements required under applicable law.

Severity of the Injury

A serious permanent injury will generally create different damages questions than a short-term condition that resolves with limited treatment.

Courts and parties may examine how an injury affected daily life and whether it caused lasting impairment.

Hospitalization and Medical Treatment

Hospital stays, surgery, specialist visits, diagnostic testing, and ongoing care can influence claimed economic damages.

Medical records can help document both the treatment received and the costs associated with it.

Lost Income and Future Medical Costs

Some injuries may prevent a person from working temporarily or permanently.

A claimant may seek compensation for qualifying lost income when supported by evidence.

Future medical expenses may also become relevant when doctors expect continued treatment.

Permanent Injuries and Quality of Life

Permanent digestive problems or permanent vision loss can significantly affect daily activities.

The effect of an injury on independence, work, family activities, and normal routines may become relevant when damages are evaluated.

When Will the Ozempic Lawsuit Be Settled?

There is no confirmed date when the entire Ozempic litigation will settle.

Large pharmaceutical MDLs can take years because courts must manage discovery, legal motions, expert evidence, individual case facts, and possible trials.

The active 2026 scheduling and discovery orders show that the federal proceedings continue to develop.

Current Litigation Timeline

MDL 3094 began in 2024 and has since moved through organizational, discovery, complaint, and case-management stages.

The NAION litigation developed later and became MDL 3163.

During 2026, both proceedings continued to receive court orders and scheduled status conferences.

Bellwether Trials and Their Role

In some MDLs, courts and parties select representative cases for bellwether trials.

These trials can provide information about how juries may view evidence, causation, liability, and damages.

Bellwether results do not automatically decide every other plaintiff’s case.

They can, however, affect how parties evaluate future litigation and settlement discussions.

How Long Could Ozempic Lawsuits Take?

No one can provide an exact timeline.

Complex drug litigation can continue for several years, particularly when scientific and legal questions are heavily disputed.

Court rulings, discovery progress, expert testimony, trials, appeals, and negotiations can all affect the duration.

Ozempic Lawsuit Statute of Limitations

A statute of limitations establishes the period during which a lawsuit must generally be filed.

Missing the deadline can lead to dismissal even when the claimant believes the underlying injury is serious.

People considering legal action should therefore avoid assuming that participation in a large MDL automatically protects every potential claim.

Why Filing Deadlines Matter

Courts enforce filing deadlines because legal claims are expected to be brought within specified periods.

Determining when the clock begins can sometimes become complicated in pharmaceutical cases.

The answer may depend on when the injury occurred, when it was discovered, and the law of the relevant state.

How Deadlines Can Differ by State

State laws do not all use the same limitations period or rules.

Some states may also apply special discovery rules or other exceptions.

Because these rules can materially affect a claim, an individual should obtain advice based on the jurisdiction that applies to their case.

Ozempic Lawsuit Evidence and Medical Records

Evidence is essential in product liability litigation.

A plaintiff generally needs more than a personal belief that a medicine caused an injury.

Records may help establish which medication the patient used, when it was taken, what condition developed, and how doctors treated that condition.

Prescription and Pharmacy Records

Pharmacy records can help confirm the name of the medicine, dosage, prescription dates, and refill history.

These details can establish an accurate medication timeline.

Insurance claims and prescribing records may provide additional support.

Medical Diagnosis and Treatment Records

Medical records can document when symptoms first appeared and when doctors diagnosed the condition.

They may also include laboratory results, imaging, procedures, specialist evaluations, and treatment plans.

These documents can become especially important when causation is disputed.

Hospitalization and Surgery Records

Some patients alleging serious gastrointestinal injuries report hospitalization or invasive treatment.

Hospital records can document the severity of a condition and the care provided.

Surgical records may also provide detailed information about what doctors found and treated.

Proof of Financial Losses

Financial evidence may include medical bills, wage records, tax documents, employer statements, or proof of other qualifying expenses.

Keeping accurate documents can make claimed economic losses easier to evaluate.

Claimants should preserve original records rather than relying only on memory.

Other GLP-1 Drugs Involved in Lawsuits

Ozempic is not the only medication involved in federal GLP-1 litigation.

The GI MDL includes claims involving several GLP-1 medicines manufactured by Novo Nordisk and Eli Lilly.

The NAION MDL also covers multiple drugs.

Wegovy Lawsuits

Wegovy contains semaglutide and is another Novo Nordisk product.

Wegovy appears among the products involved in the federal GLP-1 litigation.

Claims involving Wegovy can share factual and scientific questions with Ozempic cases, although each plaintiff’s medical circumstances remain individual.

Rybelsus Lawsuits

Rybelsus has also appeared in federal GLP-1 product liability litigation.

Court documents list it among the Novo Nordisk products involved in MDL 3094.

The exact legal issues in an individual case depend on the claimed injury and other facts.

Mounjaro Lawsuits

Mounjaro is an Eli Lilly medicine and is also involved in GLP-1-related federal litigation.

The GI MDL includes Mounjaro among the products named in the coordinated cases.

Mounjaro also appears among the drugs covered by the NAION MDL.

Trulicity Lawsuits

Trulicity is another Eli Lilly product included in the federal proceedings.

Its presence in an MDL does not mean every user has a claim or that courts have found the medicine responsible for every alleged injury.

Each plaintiff still needs to support an individual claim with appropriate evidence.

What Should Ozempic Users Know?

People currently taking Ozempic should not stop or change a prescription solely because they read about lawsuits online.

Treatment decisions should be made with a qualified healthcare professional who understands the patient’s medical history.

Patients should tell their healthcare provider about persistent or severe symptoms.

Sudden vision changes, severe abdominal symptoms, repeated vomiting, or other potentially urgent problems may require prompt medical evaluation.

Patients should also remember that litigation and medical science answer different questions.

A legal allegation does not establish medical causation, and the creation of an MDL does not mean the defendants have been found liable.

For people considering a legal claim, preserving accurate prescription and medical records can be useful.

Frequently Asked Questions About Ozempic Lawsuit

What is the Ozempic lawsuit about?

Ozempic lawsuits generally involve patients who allege that the drug caused serious injuries and that warnings about certain risks were inadequate.

Federal cases currently include gastrointestinal injury claims and separate litigation involving NAION-related vision loss.

What are people suing Ozempic for?

Claims include allegations involving gastroparesis and other gastrointestinal injuries.

Separate federal litigation includes allegations that GLP-1 drugs caused NAION and vision loss.

The manufacturers dispute allegations made against them.

Is there currently an Ozempic class action lawsuit?

The major federal personal injury cases are being managed through multidistrict litigation rather than simply as one class action.

MDL 3094 handles GI injury claims, while MDL 3163 handles NAION claims.

Who qualifies for the Ozempic lawsuit?

Potential eligibility depends on medication use, the diagnosed injury, medical evidence, timing, applicable law, and the statute of limitations.

Simply taking Ozempic does not automatically qualify someone for a personal injury lawsuit.

What injuries are included in Ozempic lawsuits?

Federal GI litigation includes claimed injuries such as gastroparesis, ileus, intestinal obstruction, ischemic bowel or colitis, certain gallbladder injuries, pancreatitis, aspiration, and other conditions.

NAION-related vision injuries are being coordinated separately.

Can I sue Ozempic for gastroparesis?

A person diagnosed with gastroparesis after Ozempic use may be able to have a potential claim reviewed.

Whether a viable lawsuit exists depends on medical evidence, causation, timing, state law, and other individual facts.

Can I sue Ozempic for vision loss?

Some patients alleging NAION after GLP-1 use are pursuing product liability claims.

Federal NAION cases are being coordinated in MDL 3163, but each potential claimant still needs an individual legal assessment.

Has anyone received an Ozempic settlement?

The major federal proceedings remain active, and current court records show continuing pretrial activity.

Readers should not confuse advertised settlement estimates with confirmed global settlement amounts or guaranteed individual payouts.

How much could an Ozempic lawsuit settlement be?

There is no guaranteed amount.

Any eventual compensation would depend on factors such as injury severity, medical expenses, lost income, long-term effects, evidence, applicable law, and the outcome of litigation or negotiations.

How long will the Ozempic lawsuit take?

There is no confirmed completion date.

Large pharmaceutical cases can take years because courts must address discovery, scientific evidence, legal motions, representative cases, and other pretrial issues.

Is the Ozempic lawsuit still active in 2026?

Yes. Federal court records show active proceedings in both MDL 3094 for GI injuries and MDL 3163 for NAION claims during 2026.

Both proceedings have had continuing court management and scheduled conferences.

What evidence do I need for an Ozempic lawsuit?

Potentially useful evidence includes prescription and pharmacy records, medical records, diagnostic results, hospital records, treatment history, and documentation of financial losses.

The evidence required for a particular case depends on the injury and applicable legal rules.

Conclusion

The Ozempic Lawsuit remains an evolving area of pharmaceutical litigation in 2026. Federal courts are separately managing gastrointestinal injury claims in MDL 3094 and NAION vision-loss claims in MDL 3163, while the manufacturers continue to dispute allegations made against them.

People researching these cases should distinguish allegations from proven facts and confirmed court developments from online predictions. There is no single guaranteed settlement value, qualification rule, or completion date for every Ozempic claim, so individual medical evidence and applicable law remain important when evaluating a potential case.